Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06219941 · ClinicalTrials.gov registry record · Phase 2
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
A Phase 2 study of Gastric Cancer and Pancreatic Ductal Adenocarcinoma, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 224
- Enrollment target
- 20
- Study locations
NCT06219941: Recruiting Phase 2 study of Gastric Cancer and Pancreatic Ductal Adenocarcinoma, sponsored by AstraZeneca.
NCT06219941 is a Phase 2 study of Gastric Cancer and Pancreatic Ductal Adenocarcinoma that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 224 participants, below the 318-participant average among 153 other Gastric Cancer trials with a reported enrollment target (30% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06219941, a Phase 2 study of Gastric Cancer and Pancreatic Ductal Adenocarcinoma, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 224 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the safety, tolerability, efficacy, pharmacokinetics (PK), and immunogenicity of AZD0901 as monotherapy and in combination with anti-cancer agents in participants with locally advanced unresectable or metastatic solid tumours expressing CLDN18.2.
Primary Outcome
To investigate the safety and tolerability, of AZD0901 monotherapy or in combination with anti-cancer agents in particpants with advanced or metastatic solid tumours expressing CLDN18.2.
Conditions Studied
Interventions
- DRUG Leucovorin
- DRUG Irinotecan
- DRUG 5-Fluorouracil
- DRUG AZD0901
- DRUG l-leucovorin
Study Locations (20)
Other
- Research Site - Melbourne
- Research Site - Murdoch
- Research Site - Randwick
- Research Site - Changsha
- Research Site - Chengdu
- Research Site - Tbilisi
- Research Site - Chūōku
- Research Site - Kashiwa
- Research Site - Kitaadachi-gun
California
- Research Site - Orange
- Research Site - Palo Alto
- Research Site - Santa Rosa
Ontario
- Research Site - Kingston
- Research Site - Toronto
Quebec
- Research Site - Montreal
- Research Site - Sherbrooke
Kentucky
- Research Site - Louisville
New York
- Research Site - Commack
Rhode Island
- Research Site - Providence
Texas
- Research Site - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 224 participants |
| Start Date | 2023-12-13 |
| Est. Completion | 2027-09-30 |
| Phase | Phase 2 |
What NCT06219941 shows while recruiting
NCT06219941 is an interventional study that assigns participants to a tested intervention. The registered 224 participants enrollment target is mid-sized for trials with a published cap, below the 318-participant average among 153 other Gastric Cancer trials with a reported enrollment target (30% lower).
The record links to 4 conditions, with Gastric Cancer appearing as the primary indexed condition, and to 5 interventions - of which Leucovorin is the first listed.
NCT06219941 names 20 study sites across 8 states, led by Other, California, Ontario.
Frequently Asked Questions
What is clinical trial NCT06219941 about?
NCT06219941 is a clinical study titled "AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2". The purpose of this study is to assess the safety, tolerability, efficacy, pharmacokinetics (PK), and immunogenicity of AZD0901 as monotherapy and in combination with anti-cancer agents in participants with locally advanced unresectable or metastatic solid tumours expressing CLDN18.2.
What is the current status of trial NCT06219941?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 224 participants. The study started on 2023-12-13. Estimated completion is 2027-09-30.
What conditions does trial NCT06219941 study?
This clinical trial studies the following conditions: Gastric Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer, Gastroesophageal-junction Cancer.
What interventions are being tested in trial NCT06219941?
The interventions under investigation include: Leucovorin (DRUG), Irinotecan (DRUG), 5-Fluorouracil (DRUG), AZD0901 (DRUG), l-leucovorin (DRUG).
Who is sponsoring clinical trial NCT06219941?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06219941 being conducted?
This trial has 20 study locations across California, Kentucky, New York, Rhode Island, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastric Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06219941's enrollment target sits among peer trials
224 49th of 153 higher than 105 of 153 other Gastric Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gastric Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
Combination of TATE and PD-1 Inhibitor in Liver Cancer
RECRUITING · Phase 2
-
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
RECRUITING · Phase 2
-
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02706561 · 224 participants · NA
Helping Men Adhere to Sexual Rehabilitation Following Prostate Cancer Surgery
- NCT04140344 · 224 participants · NA
The NOTICE Study: Neurosurgery and OrThopedIcs Communication Evaluation Study Following Lumbar Fusions
- NCT04915183 · 224 participants · Phase 2
Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer
- NCT05519878 · 224 participants · NA
Light Therapy and Occupational Therapy Fatigue Management-Based Intervention for Patients With Genitourinary Cancers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI